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Abstract
Background: Peri-operative chemotherapy is recommended for the management of colorectal liver
metastases (CRLM). The aim of this study was to examine the impact of peri-operative bevacizumab on
survival in patients with resected CRLM.
Methods: A multicentre retrospective cohort of patients with resected CRLM was analysed from the
LiverMetSurvey Registry. Patients who received peri-operative FOLFOX (group A) were compared with
those who received peri-operative FOLFOX and bevacizumab (group B).
Results: In total, 501 patients were compared (A, n = 384; B, n = 117). Group A was older (68.3 versus
62.5 years, P < 0.01), had more rectal cancers (30.7 versus 18.8%, P < 0.01) and higher carcinoembryonic
antigen (CEA) levels at diagnosis (17.0 versus 9.7 ng/ml, P = 0.043). No difference was observed regarding
primary tumour stage, synchronicity and the number or size of metastases. Post-operative infections
were more frequent in group B (4.7% versus 12.8%, P < 0.01). Peri-operative bevacizumab had no effect
on 3-year overall survival (OS) (76.4% versus 79.8%, P = 0.334), or disease-free survival (DFS) (7.4%
versus 7.9%, P = 0.082). DFS was negatively associated with primary tumour node positivity (P = 0.011)
and synchronicity (P = 0.041).
Conclusions: The addition of bevacizumab to standard peri-operative chemotherapy does not appear
to be associated with improved OS or DFS in patients with resected CRLM.
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Introduction
Colorectal cancer (CRC) is the second cause of cancer-related
death in western countries.1 Colorectal liver metastases (CRLM)
develop in nearly half of patients with CRC, and approximately
80–90% of these will initially be unresectable.2,3 Complete resec-
tion of hepatic metastases is curative in selected patients,4 and
5-year survival rates vary from 25% to 40% after a hepatectomy.5–7
However, up to 60% of patients develop recurrent metastases
within the first 2 years after a hepatic resection.8 This suggests
possible unrecognized metastatic microfoci at the time of liver
metastasectomy, and emphasizes the role of systemic chemo-
therapy in the management of CRLM. Improved 5- and 10-year
survival rates up to 58% and 36% are obtainable, respectively,
when a multimodality strategy of chemotherapy and surgery is
used.9–12 The addition of bevacizumab, a monoclonal antibody
directed against the vascular endothelial growth factor (VEGF), to
first and second line pre-operative chemotherapy for metastatic
CRC was shown to increase resectability of liver metastases and
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statistically improve overall survival (OS) and disease-free sur-
vival (DFS) in all patients with stage IV disease.13,14
The phase III clinical trial by the European Organization for
Research and Treatment of Cancer (EORTC) demonstrated that
peri-operative FOLFOX4 significantly increases DFS at 3 years in
patients with resectable CRLM.15 Chemotherapy in conjunction
with a hepatic resection has since then become the standard treat-
ment of CRLM. The current recommended regimens include
FOLFOX, XELOX, or FOLFIRI in conjunction with a targeted
biological agent such as bevacizumab in the pre-operative setting,
and cytotoxic agents alone in the post-operative setting.16–18 The
efficacy of adjuvant bevacizumab has not been demonstrated for
stage II and III CRC.19,20 As a logical extension, bevacizumab is not
recommended by expert panels to be included in the adjuvant
treatment of CRLM, unless a benefit was shown in the neoadju-
vant setting.
There is currently a paucity of data examining the addition of
bevacizumab to modern peri-operative chemotherapy in the
context of resectable CRLM. Thus, the objective of this work was
to report a retrospective analysis of a large multicentre database
on the impact of bevacizumab added to peri-operative FOLFOX
for patients with resected CRLM, focusing on OS and DFS.
Patients and methods
A retrospective review of a multicentre cohort of patients resected
for CRLM between 2002 and 2012 was conducted. Data for this
study were obtained from the LiverMetSurvey International Reg-
istry. The LiverMetSurvey is a prospective international online
database of patients with resected metastatic CRC.21 The database
includes data voluntarily registered by more than 250 centres
across 52 countries. All clinical treatment decisions pertaining to
patients within the database were made by individual clinicians
and were not standardized for this study. Demographic, tumour-
related, peri-operative treatment and survival data, as well as
duration of chemotherapy regimens were collected from the data-
base and analysed.
Patients who had undergone a liver resection for synchronous
or metachronous CRLM, and who were treated with peri-
operative FOLFOX, with or without bevacizumab, were included.
Patients under fluoropyrimidine-based, irinotecan-based regi-
mens or XELOX were excluded. Eligible patients were separated
into two groups for comparison: patients treated with peri-
operative FOLFOX (group A), and patients treated with peri-
operative FOLFOX plus pre-operative bevacizumab or peri-
operative bevacizumab (group B). The decision to utilize
bevacizumab was made by individual clinicians and was not
standardized or recorded. Data pertaining to the original resecta-
bility status of individual patients were available and were
included in this study.
OS was defined as the time period from liver metastasectomy to
the date of death or to the date of the last follow-up. DFS was
defined as the time period from liver resection to the date of
proven recurrence or the date of death. Synchronous CRLM was
defined based on the existing LiverMetSurvey definition of 6
months. A major liver resection was defined as the resection of
three or more liver segments. The term ‘peri-operative’ was used
to refer to chemotherapy regimens administered to patients prior
to and after liver surgery. A response was reported with World
Health Organization criteria in conjunction with clinical evalua-
tion as determined by LiverMetSurvey.
Group A was compared with group B based on several vari-
ables: patient demographics, primary tumour characteristics and
stage, liver metastasis characteristics, liver surgery parameters,
post-operative complications, chemotherapeutic regiments,
disease recurrence and survival. For survival analyses, the cohort
was restricted to patients who had a minimum follow-up of 12
months after a hepatectomy.
Pearson’s c2 test and the Mann–Whitney U-test were used
where appropriate. OS and DFS for individual groups were esti-
mated using the Kaplan–Meier method and then compared using
the log-rank test. A Cox’s proportional hazard multivariate regres-
sion model was constructed. Univariate analysis was first con-
ducted and associated factors with P  0.10 were included in the
multivariate analysis. Factors with P  0.05 in the multivariate
analysis were considered to be independent predictors of OS or
DFS. Given the study objective, the addition of peri-operative
bevacizumab was included in the multivariate analysis, irrespec-
tive of its statistical association in the univariate analysis. All sta-
tistical calculations were performed using SPSS Statistics (version
20, SPSS Inc., Chicago, IL, USA).
Results
Overview
A total of 501 patients from the registry over a span of 10 years
(2002–2012) met the inclusion criteria: 384 patients in group A,
117 patients in group B (66 patients received peri-operative beva-
cizumab and 51 patients received pre-operative bevacizumab).
The median follow-up time for all patients was 22 months (range:
2–203). Patients in group A were followed for a median of 25
months, compared with 14 months for patients in group B. After
restricting for a minimum of 12 months of follow-up for survival
analysis, the overall median follow-up time was 32 months (35
versus 24 months). Clinical characteristics for both groups are
listed in Table 1. Both groups were similar except for age, type of
primary cancer and carcinoembryonic antigen (CEA) levels at
diagnosis. In group B, the number of patients treated with beva-
cizumab was comparable between the first half and the second
half of the study (48% versus 53%). Patients with synchronous
liver disease underwent a resection of their primary tumour,
received chemotherapy then a hepatectomy for CRLM. In the
context of a simultaneous colorectal and hepatic resection (50
patients; 13.0% versus 10 patients; 8.5%, P = 0.343), patients
underwent pre-operative chemotherapy then surgery. The interval
between the beginning of pre-operative chemotherapy and
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Table 1 Clinical characteristics
Variables Group A, N (%) Group B, N (%) P-value
n 384 117 –
Gender
Male 251 (65.3%) 75 (64.1%) 0.809
Female 133 (34.6%) 42 (35.9%)
Age (years)
Median (range) 68.3 (56.9) 62.5 (47.2) <0.01
Primary tumour site
Colon 259 (67.4%) 95 (81.1%) <0.01
Rectum 118 (30.7%) 22 (18.8%)
T stage
I 8 (2.0%) 2 (1.7%) 0.547
II 29 (7.5%) 14 (12.9%)
III 233 (60.6%) 78 (66.6%)
IV 69 (17.9%) 21 (17.9%)
N stage
0 115 (29.9%) 32 (27.3%) 0.363
I 141 (36.7%) 38 (32.4%)
II 91 (23.6%) 35 (30.0%)
Pre-operative chemotherapy for primary cancer 71 (18.5%) 19 (16.2%) 0.641
Pre-operative radiotherapy for primary cancer 56 (14.5%) 7 (5.9%) 0.023
Synchronicity of liver metastases
Synchronous 291 (75.7%) 89 (76.0%) 0.935
Metachronous 90 (23.4%) 27 (23.1%)
Number of liver metastases
1 133 (34.6%) 35 (29.9%) 0.072
2–3 133 (34.6%) 34 (29.5%)
4–5 67 (17.5%) 25 (21.3%)
>5 41 (10.1%) 19 (16.2%)
Maximum size of metastases (mm)
Median (range) 30 (499) 30 (149) 0.897
Location of liver metastases
Unilobar 215 (55.9%) 61 (52.1%) 0.524
Bilobar 166 (43.2%) 55 (47%)
CEA at diagnosis (ng/ml)
Median (range) 17.0 (9980) 9.7 (5244) 0.043
Initial unresectable liver disease 84 (21.8%) 33 (28.2%) 0.127
Major hepatectomy 229 (59.6%) 71 (60.7%) 0.395
Two stage resection 23 (6.0%) 12 (10.3%) 0.113
Local treatment 73 (19.0%) 17 (14.5%) 0.269
Preoperative chemotherapy
Number of cycles
Median (range) 6 (17) 6 (12) 0.441
Pre-operative clinical response 0.348
Complete/Partial 233 (60.7%) 78 (66.7%)
No change/Progression 68 (17.7%) 29 (24.7%)
Post-operative chemotherapy
Number of cycles
Median (range) 6 (24) 6 (11) 0.108
Post-operative clinical response 0.423
No recurrence 133 (34.6%) 32 (27.4%)
Recurrence/Progression 121 (31.5%) 27 (23.1%)
SD, standard deviation, CEA, carcinoembryonic antigen.
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surgery in group A and B was 3 to 6 months (median 3.5 months).
In both groups, patients returned to chemotherapy within 3
months post-operatively.
Post-operative complications
Analysis of overall post-operative complications is included in
Table 2. The non-tumoural liver was not significantly different
between the two groups. The incidence of steatosis (33.2 versus
39.4%, P = 0.225), fibrosis (14.1 versus 9.8%, P = 0.253) and
sinusoidal congestion (19.7 versus 11.3%, P = 0.072) were similar
between group A and B, respectively.
Outcome
Restricting survival analyses to the patients with at least 12
months of follow-up, 280 patients remained in group A and 59
patients in group B. As seen in Figures 1 and 2, the addition of
peri-operative bevacizumab did not significantly impact the OS at
3 years (76.4 versus 79.8%, P = 0.334) and did not influence DFS
at 3 years (7.4 versus 7.9%, P = 0.082). Univariate and multivariate
analysis of prognostic factors are included respectively in Tables 3
and 4.
Discussion
CRC is a common cancer that often carries a poor prognosis,
especially when associated with liver metastases. A complete liver
resection of all metastatic disease remains the only treatment with
a potential for a cure, but peri-operative chemotherapy has been
Table 2 Post-hepatectomy complications
Variables Group A, N (%) Group B, N (%) P-value
Overall complications 114 (29.6%) 30 (25.6%) 0.673
Overall infectious complications 18 (4.7%) 15 (12.8%) <0.01
Intra-abdominal abscess 14 (3.6%) 8 (6.8%) 0.032
Wound infection 4 (1.1%) 7 (5.9%) <0.01
Hepatic insufficiency 14 (3.7%) 1 (0.8%) 0.101
Bile leak/biloma 28 (7.3%) 3 (2.6%) 0.524
Pleural effusion 19 (4.9%) 2 (1.7%) 0.106
Ileus 5 (1.3%) 3 (2.6%) 0.387
Pneumonia 8 (2.1%) 2 (1.7%) 0.739
Haemorrhage 6 (1.6%) 2 (1.7%) 0.454
Sepsis 3 (0.8%) 0 (0%) 0.325
Arrhythmia 5 (1.3%) 0 (0%) 0.204
UTI 4 (1.1%) 0 (0%) 0.254
DVT/PE 3 (0.8%) 0 (0%) 0.252
SBO 1 (0.3%) 2 (1.7%) 0.081
Percutaneous drainage 31 (8.1%) 10 (8.5%) 0.917
Reoperation 4 (1.1%) 3 (2.6%) 0.069
Duration of hospitalization [median (range), days] 10 (50) 9 (35) 0.101
UTI, urinary tract infection; DVT/PE, deep venous thrombosis/pulmonary embolism;
SBO, small bowel obstruction.
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Figure 1 Overall survival (OS) for patients treated with peri-operative
FOLFOX alone (beva-) and for patients treated with peri-operative
FOLFOX + bevacizumab (beva+)
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found to confer a benefit on survival.15,22 The addition of a bio-
logical agent such as bevacizumab to modern cytotoxic regimens
seems to improve the tumour response rate and survival in first-
line therapy for metastatic CRC,13,23,24 but little evidence is avail-
able concerning the peri-operative usage of bevacizumab in the
context of liver metastasectomy. However, as the benefit of beva-
cizumab has not been shown in the adjuvant setting in stage II or
III CRC, it is not actually recommended in the setting of resected
CRLM by expert panels, unless a beneficial effect was seen in the
pre-operative context. The present study thus examined the effect
of bevacizumab added to the peri-operative FOLFOX for resected
CRLM on survival. With data collected from the international
prospective database LiverMetSurvey, this work is one of the
largest multi-institutional retrospective studies exploring the role
of peri-operative bevacizumab in the setting of resected CRLM.
In this sudy, patients who received peri-operative FOLFOX and
those who received peri-operative FOLFOX and bevacizumab
were generally comparable in terms of baseline demographic and
disease characteristics. The initial proportion of unresectable liver
disease was comparable between the groups. The rate of major
hepatectomies was also strictly similar between the two groups. As
the duration of follow-up time was considerably shorter for group
B, the study cohort was restricted to the patients who were fol-
lowed for a minimum of 12 months. This is done in order to
increase detectable endpoints in survival analyses, and to reduce
bias potentially caused by short follow-up. No significant differ-
ences in OS or DFS were detected between patients receiving
peri-operative chemotherapy and patients who received addi-
tional peri-operative bevacizumab. The OS rates were comparable
to those reported in previous retrospective studies,25,26 whereas
rates of DFS at 3 years were comparatively lower than those
described in the literature.27 This may be as a result of the higher
proportion of patients in the present study who presented with
synchronous CRLM. Indeed, in the general CRC patient popula-
tion, 20% to 34% of liver metastases are synchronous.28,29 In the
present study, a high percentage of patients in both groups pre-
sented with synchronous CRLM. As synchronicity of CRLM is
suggested to be associated with more aggressive disease and a
worse outcome,29 this higher percentage of synchronous liver
metastatic disease may explain a lower DFS.
Pre-operative chemotherapy has been linked to more frequent
post-operative complications.15,30 Bevacizumab has likewise been
associated with potential morbidities such as arterial and venous
thromboembolism, gastrointestinal perforation, bleeding and
impaired wound healing, when added to pre-operative
chemotherapy.31–33 However, no significant differences were
described in the literature concerning the risk of increased bleed-
ing, wound or hepatic complications when bevacizumab was
stopped at least 6 weeks before surgery.32 The present study
showed that infectious complications such as wound infections
were significantly more frequent in the group having received
bevacizumab, but not thromboembolic and haemorrhagic com-
plications, suggesting that the risk of infectious complications
may exist with the use of biological agents. There was a trend
towards less sinusoidal congestion in patients treated with beva-
cizumab, which may support various reports in the literature
describing the protective effect of bevacizumab against sinusoidal
obstruction syndrome associated with oxaliplatin-based chemo-
therapy.34,35
Recurrence after post-operative chemotherapy demonstrated a
trend towards significance as an adverse prognostic factor for OS
at multivariate analysis. Independent negative prognostic factors
for DFS included primary tumour lymph node positivity and
synchronous presentation of metastases. The presence of such
clinicopathological factors probably insinuate more aggressive
tumour biology and disseminated disease in the current cohort,
and is suggestive of a less favourable prognosis. In general, these
findings are in agreement with previous reports.28,36,37 After con-
trolling for all other significant factors, the addition of bevacizu-
mab was not significantly associated with OS and DFS in
multivariate analysis.
These findings must be interpreted in light of the retrospective
nature of the present study. The disparity between the number of
patients and duration of follow-up time in each group may have
influenced the survival analyses. In addition, the presence of a
higher proportion of patients with more aggressive tumour
biology may have contributed to the lack of perceptible impact
from the addition of bevacizumab on survival.
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Figure 2 Disease-free survival (DFS) for patients treated with peri-
operative FOLFOX alone (beva-) and for patients treated with peri-
operative FOLFOX + bevacizumab (beva+)
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Table 3 Univariate analysis of factors associated with overall survival (OS) and disease-free survival (DFS)
Variables OS DFS
3 years P value 3 year P value
Age (years)
<70 73.8% 0.812 63.2% <0.01
70 67.3% 45.5%
Gender
Male 65.7% 0.371 53.1% 0.898
Female 74.4% 54.6%
Location of primary tumour
Colon 67.5% 0.205 55.2% 0.412
Rectum 72.3% 49.7%
Tumour stage
T1/T2 83.1% 0.462 57.2% 0.795
T3/T4 70.2% 54.1%
Lymph node-positive primary tumour
No 67.2% 0.673 63.6% 0.035
Yes 72.6% 52.3%
Synchronicity
No 69.1% 0.735 71.3% 0.018
Yes 67.9% 50.6%
CEA at diagnosis
5 76.5% 0.424 55.2% 0.633
>5 65.4% 55.7%
Number of metastases
1 78.2% 0.254 59.1% 0.513
>1 64.1% 51.6%
Number of metastases
3 75.5% 0.154 58.3% 0.150
>3 61.4% 48.9%
Maximum size of metastases (mm)
10 93.2% 0.022 63.8% 0.624
>10 66.3% 51.5%
Maximum size of metastases (mm)
30 68.2% 0.926 55.3% 0.457
>30 69.3% 55.2%
Major hepatectomy
No 73.8% 0.100 55.4% 0.554
Yes 67.9% 53.2%
Curative liver resection
No 52.3% 0.266 42.2% 0.203
Yes 70.0% 54.3%
Number of preoperative chemotherapy cycles
6 69.8% 0.185 45.6% 0.038
>6 64.7% 54.9%
Number of post-operative chemotherapy cycles
6 70.8% 0.774 51.3% 0.104
>6 71.7% 61.8%
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In conclusion, this work has demonstrated that while bevaci-
zumab may be important to increase the tumour response rate in
metastatic CRC, its peri-operative addition to modern chemo-
therapy does not appear to be associated with improved global
survival or survival without disease in patients with resected
CRLM.
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